BiotechTube

OK-101 + Placebo

Phase 2Completed
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Dry Eye Disease

Conditions

Dry Eye Disease

Trial Timeline

Apr 28, 2023 → Dec 15, 2023

NCT ID
NCT05759208

About OK-101 + Placebo

OK-101 + Placebo is a phase 2 stage product being developed by OKYO Pharma for Dry Eye Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT05759208. Target conditions include Dry Eye Disease.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT05759208Phase 2Completed

Competing Products

20 competing products in Dry Eye Disease

See all competitors
ProductCompanyStageHype Score
UB-312 + PlaceboVaxxinityPhase 1
25
[18F]NAV4694Navidea BiopharmaceuticalsPhase 2
44
Bromocriptine Mesilate + PlacebosTowa PharmaceuticalPhase 1/2
40
exidavnemab + Placebo ComparatorBioArctic ABPhase 2
49
Abiprubart + PlaceboKiniksa PharmaceuticalsPhase 2
47
atomoxetine + Matching PlaceboEli LillyPhase 2
52
Rosuvastatin 40mg + PlaceboHeartFlowPre-clinical
18
EvolocumabHeartFlowApproved
80
High intensity lipid loweringHeartFlowPre-clinical
18
Apixaban 5 MG + Apixaban 2.5 MG + WarfarinArtivionPhase 3
72
LanifibranorInventivaPhase 2
47
LY450139 + PlaceboEli LillyPhase 3
77
Dulaglutide + PlaceboEli LillyPhase 3
77
raloxifene + placeboEli LillyPhase 3
77
VTX958 + VTX958 + VTX958 PlaceboVentyx BiosciencesPhase 2
47
Solanezumab + PlaceboEli LillyPhase 3
77
LY450139 dihydrate + placeboEli LillyPhase 2
52
Zagotenemab + PlaceboEli LillyPhase 2
52
Donanemab + Placebo + LY3202626Eli LillyPhase 2
52
Donanemab + PlaceboEli LillyPhase 3
77

Other Products from OKYO Pharma

OK-101 0.05% + OK-101 0.1% + PlaceboPhase 2
44